Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jun;38(6):1392–1396. doi: 10.1128/aac.38.6.1392

In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii.

E Holfels 1, J McAuley 1, D Mack 1, W K Milhous 1, R McLeod 1
PMCID: PMC188216  PMID: 8092843

Abstract

The in vitro effect of the following antimicrobial agents on Toxoplasma gondii tachyzoites were studied: artemisinin ether (arteether), cycloguanil hydrochloride (cycloguanil), mefloquine, primaquine phosphate, and quinine sulfate, as well as the calcium channel blocker verapamil and the calmodulin inhibitor trifluoperazine hydrochloride. Arteether at > or = 0.5 micrograms/ml and cycloguanil at > or = 1.0 micrograms/ml inhibited T. gondii in vitro. Cycloguanil (2.5 micrograms/ml) combined with a noninhibitory concentration of sulfadiazine (25 micrograms/ml) inhibited T. gondii more than cycloguanil alone. Neither primaquine phosphate, mefloquine, nor quinine sulfate had an inhibitory effect on intracellular T. gondii. Verapamil and trifluoperazine hydrochloride were not inhibitor at lower physiologic concentrations, but higher physiologic concentrations were toxic to cell cultures in vitro and therefore our assay could not be used to assess their effects.

Full text

PDF
1392

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brossi A., Venugopalan B., Dominguez Gerpe L., Yeh H. J., Flippen-Anderson J. L., Buchs P., Luo X. D., Milhous W., Peters W. Arteether, a new antimalarial drug: synthesis and antimalarial properties. J Med Chem. 1988 Mar;31(3):645–650. doi: 10.1021/jm00398a026. [DOI] [PubMed] [Google Scholar]
  2. Bygbjerg I., Ravn P., Rønn A., Flachs H., Hvidberg E. F. Human pharmacokinetics of proguanil and its metabolites. Trop Med Parasitol. 1987 Jun;38(2):77–80. [PubMed] [Google Scholar]
  3. Canfield C. J., Milhous W. K., Ager A. L., Rossan R. N., Sweeney T. R., Lewis N. J., Jacobus D. P. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg. 1993 Jul;49(1):121–126. doi: 10.4269/ajtmh.1993.49.121. [DOI] [PubMed] [Google Scholar]
  4. Chang H. R., Jefford C. W., Pechère J. C. In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii. Antimicrob Agents Chemother. 1989 Oct;33(10):1748–1752. doi: 10.1128/aac.33.10.1748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chang H. R., Pechère J. C. Arteether, a qinghaosu derivative, in toxoplasmosis. Trans R Soc Trop Med Hyg. 1988;82(6):867–867. doi: 10.1016/0035-9203(88)90021-1. [DOI] [PubMed] [Google Scholar]
  6. Gu H. M., Warhurst D. C., Peters W. Uptake of [3H] dihydroartemisinine by erythrocytes infected with Plasmodium falciparum in vitro. Trans R Soc Trop Med Hyg. 1984;78(2):265–270. doi: 10.1016/0035-9203(84)90296-7. [DOI] [PubMed] [Google Scholar]
  7. Ke O. Y., Krug E. C., Marr J. J., Berens R. L. Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives. Antimicrob Agents Chemother. 1990 Oct;34(10):1961–1965. doi: 10.1128/aac.34.10.1961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Klayman D. L. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985 May 31;228(4703):1049–1055. doi: 10.1126/science.3887571. [DOI] [PubMed] [Google Scholar]
  9. Krogstad D. J., Herwaldt B. L., Schlesinger P. H. Antimalarial agents: specific treatment regimens. Antimicrob Agents Chemother. 1988 Jul;32(7):957–961. doi: 10.1128/aac.32.7.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lin A. J., Klayman D. L., Milhous W. K. Antimalarial activity of new water-soluble dihydroartemisinin derivatives. J Med Chem. 1987 Nov;30(11):2147–2150. doi: 10.1021/jm00394a037. [DOI] [PubMed] [Google Scholar]
  11. Mack D. G., McLeod R. Human Toxoplasma gondii-specific secretory immunoglobulin A reduces T. gondii infection of enterocytes in vitro. J Clin Invest. 1992 Dec;90(6):2585–2592. doi: 10.1172/JCI116153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mack D. G., McLeod R. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother. 1984 Jul;26(1):26–30. doi: 10.1128/aac.26.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Meshnick S. R., Yang Y. Z., Lima V., Kuypers F., Kamchonwongpaisan S., Yuthavong Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob Agents Chemother. 1993 May;37(5):1108–1114. doi: 10.1128/aac.37.5.1108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Midha K. K., Hawes E. M., McKay G., Hubbard J. W., Korchinski E. D., Keegan D. L. Plasma concentrations of trifluoperazine following single low doses. Can Med Assoc J. 1983 Aug 15;129(4):324–324. [PMC free article] [PubMed] [Google Scholar]
  15. Oduola A. M., Sowunmi A., Milhous W. K., Kyle D. E., Martin R. K., Walker O., Salako L. A. Innate resistance to new antimalarial drugs in Plasmodium falciparum from Nigeria. Trans R Soc Trop Med Hyg. 1992 Mar-Apr;86(2):123–126. doi: 10.1016/0035-9203(92)90533-i. [DOI] [PubMed] [Google Scholar]
  16. Peterson D. S., Milhous W. K., Wellems T. E. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3018–3022. doi: 10.1073/pnas.87.8.3018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rogan A. M., Hamilton T. C., Young R. C., Klecker R. W., Jr, Ozols R. F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science. 1984 Jun 1;224(4652):994–996. doi: 10.1126/science.6372095. [DOI] [PubMed] [Google Scholar]
  18. Scheibel L. W., Colombani P. M., Hess A. D., Aikawa M., Atkinson C. T., Milhous W. K. Calcium and calmodulin antagonists inhibit human malaria parasites (Plasmodium falciparum): implications for drug design. Proc Natl Acad Sci U S A. 1987 Oct;84(20):7310–7314. doi: 10.1073/pnas.84.20.7310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Watkins W. M., Chulay J. D., Sixsmith D. G., Spencer H. C., Howells R. E. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol. 1987 Apr;39(4):261–265. doi: 10.1111/j.2042-7158.1987.tb06263.x. [DOI] [PubMed] [Google Scholar]
  20. Watt G., Long G. W., Grogl M., Martin S. K. Reversal of drug-resistant falciparum malaria by calcium antagonists: potential for host cell toxicity. Trans R Soc Trop Med Hyg. 1990 Mar-Apr;84(2):187–190. doi: 10.1016/0035-9203(90)90248-d. [DOI] [PubMed] [Google Scholar]
  21. Wattanagoon Y., Taylor R. B., Moody R. R., Ochekpe N. A., Looareesuwan S., White N. J. Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol. 1987 Dec;24(6):775–780. doi: 10.1111/j.1365-2125.1987.tb03245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. White N. J. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985 May-Jun;10(3):187–215. doi: 10.2165/00003088-198510030-00001. [DOI] [PubMed] [Google Scholar]
  23. White N. J. Drug treatment and prevention of malaria. Eur J Clin Pharmacol. 1988;34(1):1–14. doi: 10.1007/BF01061409. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES